Effectiveness of antiretroviral therapy among HIV-infected prisoners: Reincarceration and the lack of sustained benefit after release to the community

Clinical Infectious Diseases

Volumn 38, Issue 12, 2004, Pages 1754-1760

  Springer, Sandra A ^a   Pesanti, Edward ^c   Hodges, John ^a   Macura, Thomas ^d   Doros, Gheorghe ^b   Altice, Frederick L ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d Connecticut Department of Correction ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRISONER; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; HIV INFECTIONS; HIV-1; HUMANS; PRISONERS; PRISONS; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 2942635069     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421392     Document Type: Article

References (55)

1. National Commission on Correctional Health Care. The Health status of soon-to-be-released inmates: a report to congress. Vol 1 and 2. Chicago: March 2002.
2. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan T. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis 2002; 35:305-12.
3. Maruschak L. HIV in prisons, 2000. Bureau of Justice Statistics Bulletin, October 2002; 1-12.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
5. Farinpour R, Miller EN, Satz P, et al. Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS). J Clin Exp Neuropsychol 2003; 25:654-70.
6. Buka SL. Disparities in health status and substance use: ethnicity and socioeconomic factors. Public Health Rep 2002; 117(Suppl 1):S118-25.
7. Dixon PS, Flanigan TP, DeBuono BA, et al. Infection with the human immunodeficiency virus in prisoners: meeting the health care challenge. Am J Med 1993; 95:629-35.
8. Flanigan TP, Rich JD, Spaulding A. HIV care among incarcerated persons: a missed opportunity. AIDS 1999; 13:2475-6.
9. Mostashari F, Riley E, Selwyn PA, Altice FL. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:341-8.
10. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28:47-58.
11. Connecticut Department of Correction. CTDOC Annual Report 2002-2003. Available at: http://www.ct.gov/doc/lib/doc/pdf/pdfreport/ annualreport2003.pdf. Accessed 24 September 2003.
12. Altice FL, Mostashari F, Selwyn PA, et al. Predictors of HIV infection among newly sentenced male prisoners. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:444-53.
13. Altice FL, Khoshnood K, Blankenship KM, et al. Determinants of HIV seroprevalence and seroincidence of new entrants to a women's prison [abstract TU.C.2655]. In: Program and abstracts of the XI International Conference on AIDS, vol. 1 (Vancouver, Canada). Stockholm: International AIDS Society, 1996:377.
14. Connecticut Department of Public Health. HIV/AIDS surveillance report: Connecticut cases reported through December 31, 2000. Available at: http://www.dph.state.ct.us/BCH/infectiousdise/pdf/Hiv_Aids% 20Annual%20Report%202000.pdf. Accessed 17 November 2003.
15. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16:767-74.
16. Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003; 169:656-61.
17. Centers for Disease Control and Prevention. Decrease in AIDS-related mortality in a state correctional system - New York, 1995-1998. MMWR Morb Mortal Wkly Rep 1999; 47:1115-7.
18. Kirstein LM, Greenblatt RM, Anastos K, et al. Prevalence and correlates of highly active antiretroviral therapy switching in the women's interagency HIV study. J AIDS 2002; 29:495-503.
19. Baillargeon J, Borucki M, Zepeda S, et al. Antiretroviral prescribing patterns in the texas prison system. Ann Epidemiol 2000; 10:474.
20. Baillargeon J, Borucki MJ, Zepeda S, et al. Antiretroviral prescribing patterns in the Texas prison system. Clin Infect Dis 2000; 31:1476-81.
21. Edwards S, Tenant-Flowers M, Buggy J, et al. Issues in the management of prisoners infected with HIV-1: the King's College Hospital HIV prison service retrospective cohort study. BMJ 2001; 322:398-9.
22. HIV/AIDS and the states: a look at laws enacted in 1998. AIDS Policy Law 1999; 14:8-13.
23. Brook MG, Jones K, Dale AW, Miller RF. Management of HIV and hepatitis B or C co-infection in 15 HIV treatment centres: disparity between protocols and practice. Int J STD AIDS 2003; 14:469-72.
24. Curtis H, Sabin CA, Johnson MA. Findings from the first national clinical audit of treatment for people with HIV. British HIV Association Clinical Audit Committee. HIV Med 2003; 4:11-7.
25. Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res 2000; 35:389-416.
26. Turner BJ, Fleishman JA, Wenger N, et al. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med 2001; 16:625-33.
27. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr 2000; 25: 115-23.
28. Baker R. 25% of HIV positive individuals not treated according to federal guidelines. BETA 1998; Jul:8.
29. Witteveen E, van Ameijden EJ. Drug users and HIV-combination therapy (HAART): factors which impede or facilitate adherence. Subst Use Misuse 2002; 37:1905-25.
30. Wood E, Montaner JS, Chan K, et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002; 16: 2065-72.
31. Stone VE, Mansourati FF, Poses RM, Mayer KH. Relation of physician specialty and HIV/AIDS experience to choice of guideline-recommended antiretroviral therapy. J Gen Intern Med 2001; 16:360-8.
32. Baillargeon J, Borucki M, Williamson J, Dunn K. Determinants of HIV-related survival among Texas prison inmates. AIDS Patient Care and STDS 1999; 13:355-61.
33. Hader SL, Smith DK, Moore JS, Holmberg SD. HIV infection in women in the United States: status at the Millennium. JAMA 2001; 285: 1186-92.
34. Lucas GM, Chaisson RE, Moore RD. Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study. J Acquir Immune Defic Syndr 2003; 33:321-8.
35. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-9.
36. Altice FL, Selwyn PA, Watson R, eds. Reaching in, reaching out: treating HIV/AIDS in the correctional community. Chicago: National Commission on Correctional Health Care Press, 2002.
37. Gallego O, Corral A, De Mendoza C, Gonzalez-Lahoz J, Soriano V. High rate of resistance to antiretroviral drugs among HIV-infected prison inmates. Med Sci Monit 2003; 9:CR217-21.
38. Stone DR, Corcoran C, Wurcel A, et al. Antiretroviral drug resistance mutations in antiretroviral-naive prisoners. Clin Infect Dis 2002; 35: 883-6.
39. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-46.
40. Deeks SG, Hirschel B. Supervised interruptions of antiretroviral therapy. AIDS 2002; 16(Suppl 4):S157-69.
41. MacGowan RJ, Margolis A, Gaiter J, et al. Predictors of risky sex of young men after release from prison. Int J STD AIDS 2003; 14:519-23.
42. Wohl DA, Shain L, Adamian M, et al. HIV transmission risk behaviors among HIV-infected individuals released from prison [abstract 36]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:70.
43. Adimora AA, Schoenbach VJ, Stancil TR, et al. Incarceration and heterosexual HIV infection among rural African Americans [abstract 486]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retroviruses and Human Health, 2000: 167.
44. Keen J, Rowse G, Mathers N, et al. Can methadone maintenance for heroin-dependent patients retained in general practice reduce criminal conviction rates and time spent in prison? Br J Gen Pract 2000; 50: 48-9.
45. Smith-Rohrberg D, Bruce RD, Altice FL. Review of corrections-based therapy for opiate-dependent patients: implications for buprenorphine treatment among correctional populations. J Drug Issues 2004; 34: 451-80.
46. Altice FL, Khoshnood K. Transitional case management as a strategy for linking HIV-infected prisoners to community health and social services (Project TLC) [monograph]. Connecticut Department of Public Health, Hartford, CT: 1997.
47. Rich JD, Holmes L, Salas C, et al. Successful linkage of medical care and community services for HIV-positive offenders being released from prison. J Urban Health 2001; 78:279-89.
48. Vigilante KC, Flynn MM, Affleck PC, et al. Reduction in recidivism of incarcerated women through primary care, peer counseling, and discharge planning. J Womens Health 1999; 8:409-15.
49. Conklin TJ, Lincoln T, Flanigan TP. A public health model to connect correctional health care with communities. Am J Public Health 1998; 88:1249-50.
50. Grinstead O, Zack B, Faigeles B. Reducing post-release risk behavior among HIV seropositive prison inmates: the health promotion program. AIDS Educ Prev 2001; 13:109-19.
51. Altice FL, Springer S, Buitrago M, et al. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health 2003; 80:416-27.
52. Mitty JA, Stone VE, Sands M, et al. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 2002; 34:984-90.
53. Clarke S, Keenan E, Ryan M, Barry M, Mulcahy F. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read 2002; 12:305-7, 312-6.
54. Fischl M, Castro J, Monroig R, et al. Impact of directly observed therapy on long-term outcomes in HIV clinical trials [abstract 528] In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 2001.
55. Babudieri S, Aceti A, D'Offizi GP, Carbonara S, Starnini G. Directly observed therapy to treat HIV infection in prisoners. JAMA 2000; 284: 179-80.